Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment.

Lin, Hung-Jun; Liang, Tien-Li; Chang, Yao-Yuan; Liu, Der-Zen; Fan, Jia-Yu; Roffler, Steve R; Lin, Shyr-Yi

Lin, Hung-Jun; Liang, Tien-Li; Chang, Yao-Yuan; Liu, Der-Zen; Fan, Jia-Yu; Roffler, Steve R; Lin, Shyr-Yi.

Afiliación

Lin HJ; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan.
Liang TL; Department of Nursing, Hungkuang University, Taichung 433, Taiwan.
Chang YY; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan.
Liu DZ; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan.
Fan JY; Medical and Pharmaceutical Industry Technology and Development Center, New Taipei 248, Taiwan.
Roffler SR; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan.
Lin SY; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.

Pharmaceutics ; 14(6)2022 Jun 05.

Article en En | MEDLINE | ID: mdl-35745775

Palabras clave

bispecific targeting antibody; liposomal drug; pancreatic cancer; targeted liposome

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google